| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/100 | Human,Mouse,Rat |
| ICC | 1/100-1/500 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | EAR2; ERBAL2; NR2F6; Orphan nuclear receptor EAR-2; V-erbA related protein EAR-2 |
| Entrez GeneID | 2063; |
| WB Predicted band size | 42kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse,Rat |
| Immunogen | Synthesized peptide derived from N-terminal of human NR2F6. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是关于NR2F6抗体的3篇代表性文献示例(内容为模拟概括，仅供参考)：
1. **文献名称**：*NR2F6 as a peripheral immune checkpoint in CD8+ T-cell-mediated autoimmunity*
**作者**：Hermann-Kleiter N, et al.
**摘要**：该研究利用NR2F6特异性抗体，通过Western blot和流式细胞术验证了NR2F6在CD8+ T细胞中的表达，揭示其通过抑制T细胞活化通路发挥免疫抑制作用。
2. **文献名称**：*Nuclear receptor NR2F6 promotes tumor immune evasion by suppressing T cell infiltration*
**作者**：Wang Y, et al.
**摘要**：通过免疫组化(使用NR2F6抗体)分析临床样本，发现NR2F6在多种癌症中高表达，并与其通过抑制趋化因子分泌减少T细胞浸润的机制相关。
3. **文献名称**：*Targeting NR2F6 in dendritic cells enhances antitumor immunity*
**作者**：Guan H, et al.
**摘要**：研究使用NR2F6抗体进行染色质免疫沉淀(ChIP)，证明NR2F6通过直接调控IL-12等基因表达抑制树突状细胞功能，靶向其可增强抗肿瘤免疫应答。
4. **文献名称**：*Developmental regulation of NR2F6 in embryonic stem cell differentiation*
**作者**：Li S, et al.
**摘要**：利用NR2F6抗体进行免疫荧光定位，发现其在胚胎干细胞向中胚层分化过程中动态表达，提示其对发育相关基因的转录调控作用。
(注：以上文献信息为示例性质，实际文献需通过PubMed/Google Scholar等平台检索确认。)
The NR2F6 antibody is a research tool targeting the nuclear receptor subfamily 2 group F member 6 (NR2F6), also known as COUP-TFIII or EAR-2. NR2F6 is an orphan nuclear receptor that functions as a transcription factor, playing roles in embryonic development, immune regulation, and cancer progression. It binds to hormone response elements in DNA, either activating or repressing target genes depending on cellular context.
In immunology, NR2F6 acts as a checkpoint in T-cell activation by suppressing IL2 and IFN-γ production, suggesting involvement in immune tolerance and tumor immune evasion. Its interaction with RORγt in Th17 cells further links it to autoimmune and inflammatory diseases. In oncology, NR2F6 is implicated in tumorigenesis through regulation of apoptosis, angiogenesis, and metastasis pathways. Overexpression has been observed in melanoma, colon, and breast cancers, while its role varies between tumor types – acting as oncogene in some contexts and tumor suppressor in others.
The NR2F6 antibody is widely used in techniques like Western blotting, immunohistochemistry, and flow cytometry to study protein expression patterns and subcellular localization. Recent studies explore its potential as a therapeutic target, particularly in overcoming resistance to immune checkpoint inhibitors. Commercial antibodies are typically validated for specificity against human, mouse, or rat NR2F6 isoforms.
×
